OXYGENTA PHARMACEUTICAL
|
The Current P/E Ratio of OXYGENTA PHARMACEUTICAL is -10.42.
| Share Price | ₹49.5 | Jun 09,2026 |
| Market Cap | ₹183.2 Cr | |
| Earnings-TTM | ₹-17.6 Cr | TTM-Standalone Results |
| Price/Earnings | -10.42x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of OXYGENTA PHARMACEUTICAL
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹183.2 Cr] as on Jun 09,2026
(/) Earnings [ ₹-17.6 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ -10.42x ]
Thus, for OXYGENTA PHARMACEUTICAL , the investors are currently willing to pay -10.42 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of OXYGENTA PHARMACEUTICAL !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of OXYGENTA PHARMACEUTICAL over the last five years.
Historical PE (Price/Earnings) ratio chart of OXYGENTA PHARMACEUTICAL
PE Ratio Performance Analysis for OXYGENTA PHARMACEUTICAL
- OXYGENTA PHARMACEUTICAL 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 0.00x.
- OXYGENTA PHARMACEUTICAL 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, OXYGENTA PHARMACEUTICAL 's p/e ratio peaked in Mar2025 at 0x.
- OXYGENTA PHARMACEUTICAL 's p/e ratio hit its five-year low in Mar2025 of 0x.
How does OXYGENTA PHARMACEUTICAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| OXYGENTA PHARMACEUTICAL | -17.58 | -10.42 | 183.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 36.92 | 426,938.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 69.84 | 179,361.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 70.81 | 151,385.0 |
| CIPLA LTD | 3,869.79 | 28.74 | 111,220.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 25.55 | 105,899.0 |
| MANKIND PHARMA LTD | 1,926.41 | 51.26 | 98,745.3 |
| LUPIN LTD | 5,355.47 | 19.32 | 103,490.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.14 | 111,264.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 23.76 | 83,208.3 |
| LAURUS LABS LTD | 889.85 | 86.48 | 76,955.9 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs OXYGENTA PHARMACEUTICAL 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | -10.42x |
| Max industry PE | 86.48x |
| Median industry PE | 28.74x |
| Average industry PE | 38.58x |
You may also like the below Video Courses